AstraZeneca warns about the risks of litigation with BMS

• AstraZeneca warns about potential litigation with Bristol Myers Squibb that could cost more than $300 billion.
• The litigation could last for several months, but the parties could not reach agreement on the extent of the uncertainty; AstraZeneca comments, BMS denies this.
• According to the estimates, the litigation could result in AstraZeneca’s plans being delayed in the US until 2030.

British drugmaker AstraZeneca has warned about potential litigation with the American company Bristol Myers Squibb (BMS), which, according to the company’s own assessment, could see its pharmaceutical group’s costs rise by more than $300 million. In the material, Financial Times reports.

In particular, the litigation could last for several months, but there is no clarity on what the uncertainty will be; AstraZeneca says it will, while BMS denies it.

The material also contains comments from AstraZeneca’s general director, Pascal Soriot. The company, which is based in Cambridge, said that, according to the terms of the deal, it may have to pay more than £196 million. BMS, headquartered in Princeton, said that it would pay $133 billion; the material also states that a UK research team without exception in Moreton, on the Wirral peninsula near Liverpool, and the company’s office for the UK and Ireland is in Uxbridge.

According to the report, the litigation could be one of the largest among companies, which, according to the report, would be settled by the fourth quarter with a total amount of cash. The material also notes that AstraZeneca plans to continue pursuing its business in the US, where the company, according to the estimates, would invest $50 billion in research until 2030. The material also states that BMS expects the results of another court case to be decided by 2026; it adds that the company’s share was set at $12.97 billion, representing a 5% increase year-on-year on the previous year’s total.

Tags: Europe/Economy